Examining gene abnormalities and their impact on lymphoma prognosis
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
This study is trying to see how certain gene changes in lymphoma patients affect their treatment outcomes and overall health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Henan Cancer Hospital Government |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT04263935 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the correlation between driver gene abnormalities and various clinicopathological characteristics in patients diagnosed with lymphoma. It involves collecting data from Chinese patients, including demographic information, treatment history, and the presence of specific gene abnormalities. The goal is to evaluate how these factors relate to treatment efficacy and overall disease prognosis, providing insights into the management of lymphoma.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with lymphoma who meet the WHO 2017 classification criteria and have a life expectancy of at least three months.
Not a fit: Patients with a history of other active malignant tumors or those deemed unsuitable by researchers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lymphoma prognosis and lead to more personalized treatment strategies for patients.
How similar studies have performed: While this study explores a specific correlation, similar observational studies have shown promise in understanding the genetic underpinnings of various cancers, suggesting potential for valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosed as lymphoma (according to WHO 2017 classification criteria) 2. Life expectancy no less than 3 months 3. Agreeing to sign the written informed consents Exclusion Criteria: 1. Other malignant tumor history or active malignant tumor need be treated 2. Researchers determine unsuited to participate in this trial
Where this trial is running
Zhengzhou, Henan
- Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Yanyan Liu, M.D. Ph.D
- Email: yyliu@zzu.edu.cn
- Phone: +8613818176375
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.